

Research Article

Bone Marrow-Derived Cells Contribute to the Maintenance of Thymic Stroma including TECs

Shami Chakrabarti⁽¹⁾,^{1,2} Mohammed Hoque,² Nawshin Zara Jamil,² Varan J. Singh,² Daniel Pollacksmith,² Neelab Meer,² and Mark T. Pezzano⁽¹⁾,^{2,3}

¹Program in Biochemistry, The Graduate Center of the City University of New York, New York, NY 10016, USA ²Department of Biology, City College of New York CUNY, New York, NY 10031, USA ³Program in Biology, The Graduate Center of the City University of New York, New York, NY 10016, USA

Correspondence should be addressed to Mark T. Pezzano; mpezzano@ccny.cuny.edu

Received 4 January 2022; Accepted 24 March 2022; Published 29 April 2022

Academic Editor: Baohui Xu

Copyright © 2022 Shami Chakrabarti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In paradox to critical functions for T-cell selection and self-tolerance, the thymus undergoes profound age-associated atrophy and loss of T-cell function, further enhanced by cancer therapies. Identifying thymic epithelial progenitor populations capable of forming functional thymic tissue will be critical in understanding thymic epithelial cell (TEC) ontogeny and designing strategies to reverse involution. We identified a new population of progenitor cells, present in both the thymus and bone marrow (BM) of mice, that coexpress the hematopoietic marker CD45 and the definitive thymic epithelial marker EpCAM and maintain the capacity to form functional thymic tissue. Confocal analysis and qRT-PCR of sorted cells from both BM and thymus confirmed coexpression of CD45 and EpCAM. Grafting of C57BL/6 fetal thymi under the kidney capsule of H2BGFP transgenic mice revealed that peripheral CD45+ EpCAM+ GFP-expressing cells migrate into the developing thymus and contribute to both TECs and FSP1-expressing thymic stroma. Sorted BM-derived CD45+ EpCAM+ cells contribute to reaggregate thymic organ cultures (RTOCs) and differentiate into keratin and FoxN1-expressing TECs, demonstrating that BM cells can contribute to the maintenance of TEC microenvironments previously thought to be derived solely from endoderm. BM-derived CD45+ EpCAM+ cells represent a new source of progenitor cells that contribute to thymic homeostasis. Future studies will characterize the contribution of BM-derived CD45+ EpCAM+ TEC progenitors to distinct functional TEC microenvironments in both the steady-state thymus and under conditions of demand. Cell therapies utilizing this population may help counteract thymic involution in cancer patients.

1. Introduction

The thymus serves as the primary lymphoid organ responsible for the development and selection of a self-tolerant T-cell repertoire [1, 2]. Thymic epithelial cells (TECs) are the most significant component of the thymic microenvironment responsible for regulating T-cell development and selection [1, 3, 4]. Thus, proper organization and maintenance of TECs are critical for a properly functioning adaptive immune system [1, 3, 5]. Despite the fundamental importance of the thymus in the development of T-cells, the thy-

mus undergoes profound atrophy relatively early in life [6–8]. Thymus degeneration is physically evident in humans starting at puberty, where the loss of functional thymic microenvironments contributes to a progressively restricted naïve T-cell repertoire, resulting in an immune system that is less capable of responding to new immune challenges [8, 9]. Thymic involution also severely restricts the ability to generate long-term, low morbidity tolerance to foreign transplants, including those of stem cell origin [10]. Understanding the signals and cell-to-cell interactions that control the development and postnatal maintenance of thymic

epithelial cells is critical to designing clinical strategies to counteract age-associated involution while enhancing thymic recovery following HSCT.

Structurally, the thymic stroma contains three compartments: (1) cortex, (2) medulla, and (3) corticomedullary junction [11]. The cortex is composed of cortical thymic epithelial cells (cTECs), defined primarily by keratin-8 expression as well as the surface expression of BP1 (CD249) and CD205, together with immature thymocyte subsets, and it is involved in positive selection and MHC restriction during T-cell development [12]. The thymic medulla is composed of medullary thymic epithelial cells (mTEC), defined by primarily keratin-5/keratin-14 expression together with UEA1 (Ulex Europaeus Agglutinin 1) binding. It is involved in the negative selection of mature single-positive (SP) thymocytes expressing autoreactive T-cell antigen receptors and the development of FoxP3+Tregs [12, 13]. The corticomedullary junction is the perivascular space between the cortex and medulla, which serves as the entry point of CD4-CD8-(DN) thymocytes to the thymus [14] as well as the location where fully mature SP naïve T-cells exit to the peripheral blood vessels [1, 5, 12].

Most epithelial tissues are known to maintain tissue homeostasis throughout their adult life through the action of progenitor or stem cell populations [15]. Previous work has shown that TECs of both the cortex and the medulla develop from common progenitors during thymic organogenesis [16-19]. The presence of progenitors restricted to each lineage has also been demonstrated [17, 20-24]. [20] identified embryonic TEC progenitors, expressing high levels of claudin-3 and claudin-4, that exclusively give rise to mature mTECs [20]. Progenitors initially expressing cTEC lineage markers [25], including the thymoproteosome subunit β 5t [26, 27] and CD205 [16], were shown to give rise to mTECs during thymic organogenesis. However, the mechanisms responsible for the maintenance of functional thymic microenvironments in the postnatal thymus remain unclear. Tissue maintenance might be mediated through stem-cell-based regeneration similar to tissues with high turnover rates, including hematopoietic, skin, and intestinal tissues [28]. Alternatively, the thymus might be maintained by replication of more differentiated cells, similar to tissues with lower turnover rates, including the liver and pancreas [29]. [9] revealed that TECs, particularly mTECs, have much higher turnover rates than previously thought and are comparable with keratinocytes [30], implying a stem-cell-based regeneration of at least mTECs. [31] identified embryonic SSEA-1+ Cld3,4^{hi} mTEC stem cells that could maintain functional mTEC regeneration, including mature mTECs and central T-cell tolerance [31]. The clonogenic activity of these SSEA-1+ Cld3,4hi TECs was rapidly decreased after birth in wild-type (WT) mice but was maintained in postnatal Rag2-deficient mice, suggesting that crosstalk previously thought to be important in maintaining an appropriately organized thymus might inhibit maintenance of mTEC stem cell activity [31].

The existence of bipotent TEPC in the postnatal thymus has also been demonstrated [17, 24, 32, 33], and they appear to be found within the cTEC population [34]. The stem cell characteristics of label retention and increased colonyforming capacity were identified within the Sca-1hi MHCIIIo TEC subset [32, 33]. In contrast, [24] demonstrated bipotent TEPC potential within the PLET1+ MHCIIhi subset [24]. These competing results suggest that more work is needed to identify the bipotent epithelial progenitor phenotype and the mechanisms responsible for postnatal TEC maintenance.

Hematopoietic stem cells (HSCs) give rise to a variety of hematopoietic cells found in the thymus, including thymocytes, B-cells, dendritic cells, and macrophages. Several recent studies identified unexpected plasticity of bone marrow-derived hematopoietic stem cell populations [35-40]. These studies suggested that bone marrow-derived HSC can give rise to a variety of different adult cell types. [36] showed that BM-derived HSCs when transplanted to irradiated hosts home to and repopulate the bone marrow [36]. They also showed that this cell population could migrate and differentiate into epithelial cells in the lung, GI tract, and skin [36]. [41, 42] showed that BM-derived HSC can give rise to hepatocytes in both rodents and humans [41, 42]. However, these studies were refuted by showing that BM-derived populations begin expressing characteristics of nonhematopoietic populations as a result of cell fusion rather than by transdifferentiation in the hepatocyte system [43, 44]. Later, [45] used a Cre-lox system to demonstrate that even though a small subset of stem cells in the presence of somatic cells undergoes spontaneous fusion, there is a part of the HSC population that can undergo transdifferentiation to contribute to the keratinocyte expressing epithelial cells in the skin during the process of wound healing [45]. They showed that BM-derived epithelial cells at the wound edges express Ki67, proving that these transdifferentiated cells are actively cycling [45]. [40] also showed that bone marrow-derived HSC could give rise to lung epithelial cells under conditions of naphthalene-induced lung injury [40]. Together, these studies showed unexpected plasticity, with BM-derived HSC giving rise to epithelial cells in different organs, but none of these studies suggested a contribution of BM-derived HSC to the maintenance of thymic epithelial or other thymic stromal components.

In this study, we describe a unique population of CD45+ EpCAM+ cells in both adult BM and thymus that expresses both the definitive hematopoietic marker CD45 and the definitive thymic epithelial marker EpCAM. Furthermore, using both organ transplant and reconstitution thymus organ culture, we show that this unique population of cells can contribute to the maintenance of nonhematopoietic components of thymic stroma, including keratin and FoxN1-expressing TECs.

2. Materials and Methods

2.1. Mice. C57BL6 control, actin H2BGFP transgenic, mRFP Rosa26 transgenic mice, and athymic nude mice purchased from Jackson Laboratory were used for this study. The ages of the mice ranged from 7 to 9 weeks. All mice were bred and maintained at the City College of New York animal facility, and all experiments were performed with approval

from the City College of New York institutional animal care and use committee.

2.2. Antibodies. The following primary antibodies were used for experiments: CD45-PE Cy7, CD45-APC Cy7, and CD45 APC (clone 30-F11, BD Biosciences, BioLegend), pankeratin (Polyclonal, Dako), EpCAM-PE (clone G8.8, eBioscience), FoxN1 (clone G-20, Santa Cruz Biotechnology), FSP1 (clone S100A4, BioLegend), Thy1.2 (clone 30-H12, BD Biosciences), CD11b (clone, BioLegend), CD11b PerCpcy5.5 (clone M1/70, BioLegend), CD4-biotinylated (clone RM4-5, BioLegend), CD8-biotinylated (clone 53-6.7, BioLegend), CD19 (clone 1D3, BioLegend), rabbit anti-GFP (Life), and CD205 (LY75/DEC-205) (clone HD30 (Millipore). We also used lineage depletion panel containing B220. As control for EpCAM staining, we used rat IgG2a, κ isotype control (eBioscience). As control for CD45 staining, we used rat IgG2b, κ isotype control (BioLegend).

The following secondary reagents were used for experiments: donkey anti-rabbit IgG-TRITC, donkey anti-rabbit IgG-Cy5, donkey anti-rabbit IgG-FITC, donkey anti-rat IgG-TRITC, donkey anti-goat IgG-FITC, and goat anti-rat IgM-TRITC (Jackson ImmunoResearch); anti-rat IgG2a-FITC, anti-rat IgM-FITC, streptavidin-APC, streptavidin-APC Cy7, and streptavidin-PerCP Cy5.5 (BD Biosciences); and streptavidin-TRITC (Southern Biotechnology Associates).

2.3. TaqMan Probes. All TaqMan probes were purchased from Thermo Fisher Scientific, including CD45 (PTPRC), CD11c, EpCAM, and 18S rRNA.

2.4. Preparation of Thymic Epithelial Cells (TECs). Thymic lobes were extracted from humanely euthanized mice in ice-cold phosphate-buffered saline (PBS). The thymic lobes were cleaned to remove fat and connective tissue and cut into four smaller pieces and transferred into a new tube containing PBS. The cut pieces were gently agitated using a glass Pasteur pipette to remove thymocytes. The remaining tissue was dissociated using collagenase D (1.8 mg/ml) and DNase I (1x) in HBSS solution incubated in a 37°C water bath for 15 minutes with gentle agitation every 5 minutes using a Pasture pipette. The single-cell suspension of digested tissue was washed with PBS and then filtered through a $100 \,\mu m$ strainer to remove any clumps of tissue. Hematopoietic cells were removed from the single-cell suspension using antimouse Thy1.2, CD11b, and CD19 antibodies and magnetic beads to enrich the TEC population before sorting or flow cytometric analysis.

2.5. Isolation of Bone Marrow Cells. Bone marrow cells were isolated from mouse hind limbs, as previously described [46]. The resulting single-cell suspension was lineage depleted using biotinylated CD19, CD4, CD8, CD11b, CD11c, B220, Ter119 antibody, and biotin-binder magnetic beads. The postdepletion cell population was used for flow cytometric analysis.

2.6. Flow Cytometry. Cells were suspended at 10^6 cells/100 μ l concentration in FACS staining buffer (FSB-5% fetal bovine serum, 5 mM EDTA in PBS) and incubated with Fc-block After incubation, cells are washed and resuspended at 10⁶ cells/100 μ l concentration again in FSB with appropriately diluted primary antibodies for 20 minutes on ice in the dark. After washing, secondary antibodies appropriately diluted in FSB were added, and the cells were incubated for an additional 20 minutes on ice in the dark. After washing, the cells were resuspended in 500 μ l of FSB for data acquisition. Data acquisition was performed using an LSRII analyzer complete with three lasers (BD Biosciences), and cell sorts were performed using a FACS Aria (BD Biosciences). FACS data were analyzed using FlowJo software (Tree Star) or FACS Diva software (BD Biosciences). For FACS analysis, we have routinely used the Forward Scatter (FSC) area versus Side Scatter (SSC) area analysis to discriminate the appropriate live cell populations together with 7AAD staining. Doublet discrimination was performed using SSC W vs. SSC H followed by FSC W vs. FSC H. The single cells are then negatively selected for CD11b, CD11c, and CD19 staining to exclude thymic DCs, macrophages, and B-cells from our population of interest. To control for nonspecific binding by the antibodies, gates for positive staining were set using isotype controls and/or one minus controls. To accurately set gates for GFP expression, C56BL6 mouse analysis controls stained with the same antibody cocktail were used. We additionally used 7AAD staining for live-dead discrimination when we used irradiated C57BL6 mice for our experiment to exclude the high proportion of radiation-induced dead cells.

2.7. RNA Extraction and qRT-PCR from Sorted Cells. Cells were sorted as described above, and RNA was isolated using the Trizol method as directed by the Qiagen RNA isolation mini-prep kit. Isolated RNA was used for cDNA synthesis using reverse transcriptase and random hexamers. The resulting cDNAs were used for qRT-PCR analysis using TaqMan probes for CD45 and EpCAM. The 18S rRNA housekeeping gene was used as a positive control to normalize the qPCR results.

2.8. Reaggregate Thymic Organ Cultures (RTOCs). EpCAM+ CD45+ cells were isolated and sorted to greater than 95% purity from the bone marrow and thymus-derived from actin H2BGFP mice and placed in single-cell suspensions as described above. The resulting highly purified EpCAM+ CD45+ GFP+ cells were mixed with dissociated fetal thymic stromal cells from an E14.5 C57BL6 fetal thymus at a ratio of 1:10 to form a reaggregate on a polycarbonate filter suspended over a transwell plate. After 48 hours of culture, these reaggregates were then surgically transplanted under the kidney capsule of athymic nude mice and grown for three weeks in vivo. After three weeks, the reaggregates were harvested and sectioned for further IHC analysis.

2.9. Organ Transfer Experiments. Fetal thymi were isolated from E14.5 C57BL6 or actin H2BGFP mice, as stated, and 5-6 fetal lobes were placed under the kidney capsule of either actin H2BGFP mice or Rosa26 mRFP mice, respectively. Following a time course of 3, 6, 9, or 12 weeks, the kidneys

were isolated, and most of the exogenous thymi were used for flow cytometric analysis, while the remaining lobes were used for immunohistochemistry.

2.10. Immunohistochemistry of Thymic Sections. Thymi were embedded in OCT compound from Tissue-Tek and snapfrozen using Liquid-N₂. 8 μ m sections were cut using a cryostat and mounted on coated slides. The slides were then airdried and fixed in 4% paraformaldehyde for 10 minutes, washed with PBS three times, then permeabilized using acetone for 10 minutes, and washed and blocked with complete normal donkey serum (1% normal donkey serum in bovine serum albumin). Appropriately diluted antibodies specific to stromal subsets were added to the slides and then placed into a humid chamber at 4°C overnight. Secondary antibodies were applied, if needed, and incubated in a humid chamber for one hour at 37°C. After incubation, the slides were washed in PBS three times and mounted; then, they were sealed following the application of ProLong Gold antifade +DAPI reagent. Images were acquired using a Zeiss LSM800 confocal microscope or an LSM710 confocal microscope. Confocal images were analyzed using LSM software (Zeiss).

2.11. Statistical Analysis. Data comparisons were performed using a nonparametric, unpaired, one-tailed *t*-test. All graphs and statistical results were generated using GraphPad Prism software. A P value of <0.01 was considered significant.

3. Results

Cells coexpressing both the definitive thymic epithelial marker EpCAM and the hematopoietic marker CD45 are present in both the bone marrow and the thymus.

3.1. Presence of CD45+ EpCAM+ Cells in the Thymus. Using standard enzymatic digestion of thymic tissue in conjunction with CD45 magnetic bead depletion to reduce the frequency of hematopoietic cells, we observed a persistent but rare population of cells that coexpressed both CD45+ and EpCAM+ (DP), shown in Figure 1(b). This population has been described in several publications; however, they were identified as thymic nurse cells, which are complexes of cTECs with internalized CD45+ thymocytes [47]. Due to the consistent presence of this DP population, even after very conservative doublet discrimination, we set out to determine if this unusual population truly represented thymic nurse cells or was a unique previously undescribed cell population expressing both CD45 and EpCAM. We enhanced the isolation of this population by depleting hematopoietic cells in our enzymatically dissociated thymic tissue using a cocktail of antibodies, including anti-Thy1.2, CD11b, CD11c, and CD19 together, rather than the usual an anti-CD45 antibody. Figure 1 shows a representative FACS profile demonstrating the increase in the frequency of the CD45+ EpCAM+ population when anti-CD45 depletion was not utilized to deplete hematopoietic cells. Figure 1(a) shows that when anti-CD45 depletion was used to analyze the frequency of DP cells present in 8-month-old C57BL/6 mice, the CD45+ EpCAM+ population represents only an average of 0.0.084% (+/-0.5%) of the total cells present, whereas in Figure 1(b), when a cocktail of anti-Thy1.2, CD11b, CD11c, and CD19 was used for depletion, the frequency of the CD45+ EpCAM+ population in the total dissociated thymic cells increased to an average of 1.5% (+/-0.3%). Every set of experiments had four replicates. Our gating strategy including stringent doublet discrimination, lineage-negative selection along with the isotype control for the EpCAM antibody is shown in Supplemental Figure 1(H-M).

3.2. Thymic CD45+ EpCAM+ Cells Coexpress Both CD45 and EpCAM at Both the Protein and mRNA Levels. We reasoned that the apparent coexpression of CD45 and EpCAM, observed using flow cytometry of dissociated thymic tissue, could be the result of epitope sharing caused by the close association of thymocytes with thymic epithelial cells, due to penetration of CD45 antibodies into partially damaged TNC complexes or because of EpCAM expressing thymic dendritic cells (DCs) [48]. To confirm the presence of single cells coexpressing both CD45 and EpCAM, CD45+ EpCAM + cells were sorted to high purity (~98% purity) using a FACS sorter from dissociated thymic tissue using conservative doublet discrimination. Cells were also gated to exclude hematopoietic cells using a cocktail of anti-Thy1.2, CD11b, CD11c, and CD19. To confirm that the DP population expressed both the CD45 and EpCAM genes at the RNA level, RNA was isolated from CD45+ EpCAM+, CD45+, and EpCAM+ cell populations sorted from thymic tissue with high purity for and used for RNA isolation. For the CD45+ EpCAM+ population, we were able to achieve greater than 99% purity with the aid of back gating. For the CD45+ EpCAM- and CD45-EpCAM+ control populations, we achieved greater than ~96% purity. The sort purity results are shown in Supplemental Figure 2(A-E). We also sorted the lineage-positive population to determine the relative expression of CD11c to ensure that the DP population was not CD11C-expressing thymic dendritic cells which have been reported to express EpCAM [48]. All RNA samples were normalized to $5 \text{ ng}/\mu$ l before performing qPCR. 18S rRNA was used as a housekeeping gene to compare relative amounts of RNA expression (Figures 2(b)-2(d)). Isolated and normalized RNA was analyzed using qRT-PCR with TaqMan primers specific to EpCAM and CD45. Relative levels of RNA expression of both CD45 and EpCAM were normalized in each sorted population to the levels of 18S rRNA, to thoroughly rule out epitope sharing as the cause of this unique population. Figure 2 shows the fold change in the expression level for both CD45 and EpCAM between the two control populations (CD45+ EpCAM- and CD45-EpCAM+) and the CD45+ EpCAM+ population. Figure 2(a) shows the FACS representation of the sorted populations. Figure 2(b) shows the relative CD45 expression in all three populations, where the CD45+ EpCAM- population serves as the positive control. As expected, the CD45+ control population has a high level of CD45 expression, whereas the EpCAM+ population has negligible (~98-fold lower)



FIGURE 1: An alternative hematopoietic cell depletion method reveals a previously unidentified CD45+ EpCAM+ population in the thymus. FACS profiles show viable single cells gated on CD11c-, CD11b-, and CD19- cells. (a) Shows the presence of only 0.084% of CD45+ EpCAM + cells present in dissociated thymic tissue when using the sheep-anti-CD45 antibody followed by antisheep magnetic beads for the depletion of hematopoietic cells. (b) Shows enrichment of the CD45+ EpCAM+ population to 1.5% derived from dissociated thymic tissue when a cocktail of sheep anti-Thy1.2, anti-CD11b, anti-CD11c, and anti-CD19 antibodies followed by antisheep magnetic beads was used in place of anti-CD45. A minimum of three replicates of all experiments were performed.

CD45 expression compared to the CD45 only population. The DP population expressed ~80-fold more CD45 than the CD45- EpCAM+ TEC population but only had a ~10fold lower expression of CD45 than the CD45+ EpCAMpopulation. Figure 2(c) shows the relative EpCAM expression in all three populations, where the CD45-EpCAM+ population was used as a positive control. DP cells exhibited ~37-fold higher EpCAM expression than the CD45+ population, while expression of EpCAM was ~60fold lower than that observed in the EpCAM only TEC positive control. As expected, the CD45 only population has negligible EpCAM expression (~97-fold lower). The qRT-PCR confirmed that the DP population coexpressed both CD45 and EpCAM mRNA. Analysis of CD11c expression demonstrated a high level of CD11c expression in the lineage-positive population; however, negligible CD11c expression (~96-fold lower) was observed in the lineage-depleted EpCAM- CD45+, CD45- EpCAM+, and CD45+ EpCAM+ populations (Figure 2(d)). The absence of CD11c mRNA expression in the CD45+ EpCAM+ population showed that this new population is not CD11C + EpCAM+ thymic DC and represents a previously undescribed subset. The expression of both the CD45 and EpCAM surface proteins by sorted CD45+ EpCAM+ cells was verified using immunohistochemistry. CD45+ EpCAM- or CD45- EpCAM+ subsets were also sorted as controls and immediately imaged under a fluorescence microscope without further staining to ensure that the antibodies were specific and that the CD45+ EpCAM+ cells observed using flow cytometry were indeed single cells coexpressing both CD45 and EpCAM surface proteins. Figures 2(e)-2(s) show the fluorescent microscopy imaging

results obtained using the sorted CD45+ EpCAM+ population and the control CD45+ EpCAM- or CD45-EpCAM+ populations from C57BL6 thymus following anti-CD45 antibody and anti-EpCAM antibody staining. Combined CD11b, CD11c, and CD19 staining was performed on all sorted populations to rule out Langerhans cells and thymic DCs that are known to coexpress EpCAM (48-50) as well as to rule out nonspecific binding of the anti-CD45 and anti-EpCAM antibodies to FC receptors on hematopoietic cells, leading to a false-positive result. The CD45+ EpCAM- control cells showed staining with only the anti-CD45 antibody (Figures 2(o)-2(s)). The CD45-EpCAM+ control cells only exhibited anti-EpCAM staining (Figures 2(j)-2(n)). However, the CD45+ EpCAM+ cells stained strongly with both the anti-CD45 and anti-EpCAM antibodies while no staining with a cocktail of anti-CD11b, CD11c, and CD19 antibodies was observed (Figures 2(e)-2(i)) and confirming that the staining observed was not the result of nonspecific Fc-receptor binding. In each IHC panel, insets added to each panel show images of additional cells to verify the results. IHC results of the sorted cells confirmed protein coexpression of both CD45 and EpCAM on the CD45+ EpCAM+ population.

To provide further evidence for the presence of this unique population and to localize the cells within the thymus, we sought to determine if the DP population could be seen within sections of an intact adult mouse thymus. Within adult mouse thymus, CD45+ cells far outnumber and are close to TECs. To better visualize the rare DP cells, within the background of abundant CD45+ thymocytes, we performed intraperitoneal injections of dexamethasone on



FIGURE 2: Single sorted thymic CD45+ EpCAM+ cells express both the CD45 and EpCAM surface proteins as well as mRNA for both genes. CD45+ EpCAM+ cells were sorted to high purity and analyzed for CD45 and EpCAM expression using immunofluorescence microscopy and qRT-PCR. CD45+ EpCAM- and CD45- EpCAM+ cells were sorted as controls. (a) FACS analysis representation of the gating strategy used for the sorting of the EpCAM+ CD45-, EpCAM+ CD45+, and EpCAM-CD45+ populations subsequently analyzed by qPCR and histology. (b) Shows the relative CD45 mRNA expression level in the thymus-derived CD45+ EpCAM+ cells compared to the CD45+ EpCAM+ and CD45- EpCAM+ control populations. (c) Shows the relative EpCAM mRNA expression level in the thymus-derived CD45+ EpCAM+ cells compared to the CD45+ EpCAM+ control populations. (c) Shows the relative EpCAM+ control populations. (d) Shows the relative CD11c mRNA expression level in the thymus-derived CD45+ EpCAM+ control populations. (e-i) DIC image, EpCAM+ control populations. (d) Shows the relative CD11c, and CD45- EpCAM+ control populations. (e-i) DIC image, EpCAM staining (red), and CD45 staining (green); CD11b, CD11c, and CD19 staining (blue); and merged (CD45 and EpCAM) image, respectively, for CD45+ EpCAM+ experimental population; (j-n) DIC image, EpCAM staining (red), and CD45- EpCAM+ control population; (o-s) DIC image, EpCAM staining (red), and CD45 staining (green); CD11b, CD11c, and CD19 staining (blue); and merged (CD45- and EpCAM) image, respectively, for CD45+ EpCAM- control population. Insets added to each panel show additional cells from other images of the same experiment. A minimum of three replicates of all experiments were performed.

6-week-old C57BL/6 mice to specifically reduce the number of double-positive thymocytes, the most abundant CD45+ cells in the thymus. Three days following the dexamethasone injections, when the number of thymocytes is most reduced, the mice were sacrificed, and their thymi were harvested, sectioned, and stained with antibodies specific to CD45 (hematopoietic) and pan-keratin (epithelial) to enable identification of thymic stromal cells coexpressing CD45 and



FIGURE 3: Single sorted bone marrow-derived CD45+ EpCAM+ cells express both the CD45 and EpCAM genes and surface proteins. CD45 + EpCAM+ cells were sorted to high purity and analyzed for CD45 and EpCAM expression using immunofluorescence microscopy, as well as qRT-PCR. CD45+ EpCAM- cells were also sorted as a control. (a) FACS profile of the gating strategy used for sorting the CD45+ EpCAM + and CD45+ EpCAM- populations from the bone marrow subsequently analyzed for mRNA expression using qPCR and protein expression by histology. (b) Shows the relative CD45 mRNA expression level in the sorted BM-derived CD45+ EpCAM+ cells compared to the CD45+ EpCAM- control population; (c) shows the relative EpCAM mRNA expression level in the sorted BM-derived CD45+ EpCAM+ cells compared to the CD45+ EpCAM- control population. (d–h) DIC image, EpCAM staining (red), and CD45 staining (green); CD11b, CD11c, and CD19 staining (blue); and merged (CD45 and EpCAM) image, respectively, for CD45+ EpCAM+ experimental population. (i–m) DIC, EpCAM staining (red), and CD45 staining (green); CD11b, CD11c, and CD19 staining (blue); for CD45+ EpCAM- control population. A minimum of three replicates of all experiments were performed.

EpCAM. Confocal imaging of the stained sections revealed rare cells that share both hematopoietic (CD45+) and epithelial (pan-cytokeratin) characteristics in the intact thymus (Supplemental Figure 3). Together, the IHC and qRT-PCR results obtained with highly purified sorted cells from mouse thymus and IHC of sections of intact thymus confirmed that the CD45+ EpCAM+ cell population observed in dissociated thymic preparations truly coexpress CD45 and EpCAM at both the protein and mRNA levels. Further, these results suggest that we and others in the field may be losing a large percentage of EpCAM+ cells by ignoring this CD45+ EpCAM+ population, including potential TEC progenitors.

3.3. Rare CD45+ EpCAM+ Cells Are Present in the Bone Marrow. Bone marrow-derived cells, including hematopoietic stem cells (HSCs), were previously reported as contributors of epithelial cells for epithelial organs, including the lung [40], gut, and uterus through the process of transdifferentiation [36]. Wong et al. showed that the BM-derived CD45+ CCSP+

cell population contributes to the alveolar epithelial cell population (CCSP is a unique alveolar epithelial cell marker) [39, 40]. As the DP population is expressing the hematopoietic marker CD45, we wanted to determine if the CD45+ EpCAM+ cells observed in the thymus might be derived from a population in the BM. Bone marrow preparations were analyzed for the presence of CD45+ EpCAM+ cells using flow cytometry. Multiple experiments with C57BL6 bone marrow showed that bone marrow contains a low frequency (~0.1%-0.2%) of CD45+ EpCAM+ cells (Figure 3(a)). Our gating strategy including doublet discrimination, lineage-negative cell population selection along with isotype control staining for the EpCAM antibody is shown in Supplemental Figure 1(A-F). We have also shown the presence of the CD45+ EpCAM+ cell population in athymic nude mice in Supplemental Figure 1G. The presence of the CD45+ EpCAM+ cell population in nude mouse bone marrow confirms this population originates in the bone marrow and does not migrate from the thymus to the bone marrow. CD45+ EpCAM+ cells could not be identified in dissociated nude mouse thymus (data not shown).

To confirm that the population of CD45+ EpCAM+ cells detected in flow cytometry analysis represented a new population coexpressing both the CD45 and EpCAM proteins on their surface and expressed at the mRNA level, we performed the same set of experiments shown above for the thymic-derived CD45+ EpCAM+ population using sorted BM-derived cells. CD45+ EpCAM+ cells and CD45+ EpCAM cells (control) were sorted to high purity (~99%) from a bone marrow preparation depleted of lineage-committed cells and stained with CD45 and EpCAM antibodies. Bone marrow sort purity results are shown in Supplemental Figure 2(E-G). The sorted populations were subsequently analyzed using immunohistochemistry and qRT-PCR for the expression of CD45 and EpCAM for each of the sorted cell populations.

To rule out epitope sharing as the cause of the bone marrow-derived DP population, we determined the relative level of mRNA expression of both CD45 and EpCAM compared to the housekeeping gene, 18S rRNA. All RNA samples isolated for these experiments were diluted to $5 \text{ ng}/\mu l$, to exclude differences in RNA amounts and normalized to 18S rRNA. The CD45+ EpCAM+ population was shown to express both CD45 and EpCAM mRNA using qRT-PCR (Figures 3(b) and 3(c)). Figure 3(b) shows the relative CD45 expression in the CD45+ EpCAM+ population when compared with the CD45+ EpCAM- positive control population. As expected, the CD45+ population has a high level of CD45 mRNA expression. The DP population clearly expresses CD45 mRNA. However, it has ~51-fold lower expression than the CD45+ EpCAM- control population. Figure 3(c) shows the relative EpCAM expression in comparison to the CD45+ EpCAM- negative control population. The CD45+ EpCAM+ population has ~93-fold higher EpCAM mRNA than the CD45+ EpCAM- control population.

The sorted DP and CD45 only populations in the BM were also analyzed using immunohistochemistry for surface protein expression of CD45, EpCAM, and a mixture of CD11b, CD11c, and CD19 for each of the populations (Figures 3(d)-3(m)). CD11b, CD11c, and CD19 combined staining was done to rule out F_C receptor binding to the CD45 and EpCAM antibodies leading to a false-positive result as well as ensuring that the CD45+ EpCAM+ cells observed were not CD11c-expressing DCs. The control CD45+ EpCAM- population only exhibited staining with the anti-CD45 antibody (Figures 3(i)-3(m)). In contrast, the CD45+ EpCAM+ cells were stained with both the anti-CD45 (Figure 3(f)) and anti-EpCAM antibodies (Figure 3 (e)) while no staining with the CD11b, CD11c, and CD19 cocktail (Figure 3(g)) was observed. Insets in each IHC panel show additional cells from other images. Together, these IHC results of sorted cells confirmed that single CD45+ EpCAM+ cells coexpress both the CD45 and EpCAM proteins on their cell surface. Isotype control staining was used to verify the specificity of the EpCAM and CD45 antibodies (data not shown).

Collectively, these data show that there is a rare population of previously undescribed cells in both the adult thymus and the bone marrow that coexpress the hematopoietic marker CD45 and the definitive thymic epithelial marker EpCAM. Further, we have demonstrated that in both adult bone marrow and thymus, single cells express both the CD45 and EpCAM surface proteins and that highly purified sorted populations express mRNA for both genes confirming that this rare and unique population exists. The absence of TNC complexes ensures that contrary to previous reports when careful double discrimination is used, the DP cells are not TNCs, while the absence of CD11c, CD11b, and CD19 surface protein expression allows exclusion of F_C receptor binding to antibodies or identification of Langerhans cells and thymic DCs which are known to express both CD11c and EpCAM [48, 49].

3.4. CD45+ EpCAM+ Cells Are Recruited to Thymic Stroma from the Periphery and Contribute to EpCAM+ CD45-TECs. To understand if peripheral CD45+ EpCAM+ cells can contribute to the nonhematopoietic populations of the thymic stroma, E14.5 C57BL/6 fetal thymic lobes were transplanted under the kidney capsule of actin H2BGFP transgenic mice. The engrafted thymic lobes were then harvested at different time points from 3 to 12 weeks following transplant and analyzed for the presence of H2B-GFPexpressing cells that have migrated into and contributed to the growing fetal thymi using both flow cytometry and immunohistochemistry. As a control, E14.5 C57BL/6 fetal thymic lobes were transplanted under the kidney capsule of C57Bl6 mice and harvested after three weeks for flow cytometric analysis to set up negative gating for GFP expression.

Figure 4(a) shows representative FACS analysis of dissociated transplanted thymic lobes analyzed at different time points after transplant, Figure 4(b) shows the percentage of CD45+ EpCAM+ GFP+ cells migrating into the C57BL/6 GFP-negative thymus, and Figure 4(c) shows the frequency of CD45- EpCAM+ GFP+ TECs that are derived from peripheral sources. Bar graphs of the mean percentages of peripheral CD45+ EpCAM+ GFP+ and CD45- EpCAM+ GFP+ populations found in the transplanted thymi are shown in Figures 4(d) and 4(e).

The flow cytometric analysis revealed an influx of GFP+ CD45+ EpCAM+ cells into the engrafted fetal thymic lobes. The presence of CD45- EpCAM+ GFP+ TECs was detected at a later time point in the C57BL/6 grafts (Figure 4). An influx of the peripherally derived CD45+ EpCAM+ GFP+ population was observed at every time point. The average frequency of the CD45+ EpCAM+ GFP+ population remained almost constant at week three, 17.88% (+/-7.3%), and week six, 18% (+/7.9%). At week nine and week twelve, the average frequency of the CD45+ EpCAM+ GFP+ population increased to 26.53% (+/-19%) and 27.3% (+/-13%), respectively. An unpaired, nonparametric one-tailed t-test demonstrated that there was a significant increase in the frequency of peripherally derived GFP+ CD45+ EpCAM+ cells within the C57BL6 fetal thymi that were transplanted under C57BL6 kidney capsules when compared with C57BL/6 control thymi transplanted under the kidney capsules of non-GFP-expressing mice.



FIGURE 4: A peripheral population can contribute both CD45+ EpCAM+ cells and CD45-EpCAM+ TECs in the thymus. C57BL6 fetal thymi were transplanted under the kidney capsule of actin H2BGFP mice and analyzed for the presence of GFP-expressing cells at 4 time points 3 to 12 weeks after transplant using FACS. (a) The FACS representation of the lineage-depleted cells derived from dissociated engrafted thymi gated for CD45 and EpCAM. (b) The FACS representation of the percentage GFP+ cells within the CD45+ EpCAM+ subset found in the grafted thymus and (c) the FACS representation of the percentage GFP+ cells within the CD45- EpCAM+ population at the different time points after transplant under the kidney capsule. (d) Bar graph showing the mean percentage of the GFP-expressing cells found within the CD45+ EpCAM+ cell population at different time points (error bars represent SEM). (e) Bar graph showing the mean percentage of the GFP-expressing cells found within the CD45- EpCAM+ TEC population at different time points (error bars represent SEM). "*" indicates a statistically significant difference between control and any time point. *P* values for each *t*-test analysis are given with the bar graph. The results presented are representative of the three to five replicates of each experiment that were performed.

We compared each time point with the control. All the time points analyzed, when C57BL/6 fetal lobes were transplanted under the kidney capsule of actin H2BGFP mice, showed a statistically significant number of CD45+ EpCAM+ GFP+ cells had migrated to the transplanted thymi.

Interestingly, a small but progressive increase in the frequency of CD45- EpCAM+ GFP+ TECs was also observed, suggesting that true EpCAM-expressing TECs were also derived from peripheral sources. The average frequency of GFP-expressing TECs increased from 2.6% (+/- 2%) at week three to 4.4% (+/- 2%) at week six. At week nine, the average frequency of GFP-expressing TECs was 6.34% (+/- 4%) and increased to 7.4% (+/- 4%) at week twelve. C57BL/6 fetal thymi transplanted under the C57BL/6 kidney capsule were used as a control to allow gating on true GFP-expressing cells in the engrafted thymus. When the frequency of EpCAM+ GFP+ cells in the engrafted thymi at each time points was compared to the control (using a nonparametric, unpaired, one-tailed *t*-test), it showed significant numbers of EpCAM+ GFP+ true TECs appearing in the transplanted thymic lobes. These results confirm that peripheral GFP+ CD45+ EpCAM+ cells migrate into the thymus and that these peripheral cells then give rise to GFP-expressing CD45- EpCAM+ thymic epithelial cells. This result is unprecedented, as it suggests that contrary to previous models of thymic organogenesis, which suggested that all EpCAM-expressing TECs were derived from the third pharyngeal pouch endoderm and its derivatives, that in fact, up to 7% of EpCAM only TECs may be derived from peripheral sources that migrate into the thymus.

3.5. Peripheral Cells Contribute to the Pan-Keratin and FoxN1 Expressing Epithelial Cells in the Thymic Stroma. The engrafted thymi were also analyzed histologically in parallel experiments at the previously indicated time points. Figure 5 shows the staining pattern of PanK (an epithelial cell marker) and FoxN1 (a definitive thymic epithelial cell marker) in the transplanted thymic tissues at different time points following transplant. These histological results showed the presence of a PanK+ FoxN1+ H2B-GFP+ and PanK+ FoxN1- H2BGFP populations in the engrafted fetal thymus at week three and week six, and PanK+ FoxN1+ H2B-GFP+ cells appeared in higher number at later time points (week nine and week twelve) shown in Figure 5. The expression of PanK on a GFP+ cell in the transplanted thymi indicates that peripheral cells can migrate into the thymus and contribute to true TECs. At earlier time points, only PanK+ FoxN1- GFP+ cells were observed, while at later time points, PanK+ FoxN1+ GFP+ cells were observed. This sequential emergence of two different populations of PanK+ GFP+ cells that were initially FoxN1- followed by FoxN1+ cells with progressive age indicates that first peripheral cells are recruited to the thymus and differentiate into only PanKexpressing TEC, and at a later time point, more mature PanK+ FoxN1-expressing cells emerge. Images of 12th week transplanted fetal thymus staining for pan-keratin and DAPI at lower magnification (200x) are shown in Supplemental Figure 4 as a representative figure to show the morphology

of fetal transplanted thymus. Supplemental Figure 4A-C shows week 12 images of the transplanted fetal thymus. In this figure, the kidney is visible in the lower part of each image. This figure clearly shows a properly developed transplanted thymus at the $12^{\rm th}$ week.

3.6. CD45+ EpCAM+ Cells Can Contribute to the Thymic Stroma In Vivo. To understand the differentiation potential of the CD45+ EpCAM+ population in vivo, we used reaggregate thymic organ culture (RTOC). GFP+ CD45+ EpCAM+ cells were sorted to high purity (greater than 95%) from actin H2BGFP mouse bone marrow or thymus and reaggregated with dissociated fetal thymic cells (E14.5) derived from GFP- C57BL6 mice. Reaggregates were cultured for 48 hours on polycarbonate filters supported by transwell plates and then engrafted under the kidney capsule of athymic nude mice. The resulting ectopic thymic graft incorporated the GFP+ CD45+ EpCAM+ population into the thymic stroma. At week three, we observed PanK and FoxN1expressing GFP+ cells in thymic stroma (Figure 6). RTOCs derived from bone marrow had GFP+ TECs, shown in Figures 6(a)-6(g). Figures 6(a)-6(d) show that bone marrow-derived CD45+ EpCAM+ cells could give rise to the thymic epithelium and prove that peripheral cells contribute to the TEC component of the thymic stroma. Images of sections of transplanted RTOCs stained for pan-keratin and DAPI at lower magnification (200x) are shown in Figures 6(e)-6(g). In this figure, the kidney is visible in the lower part of each image. The figure shows extensive pankeratin staining in both bone marrow-derived and thymusderived RTOCs indicating a properly developing reaggregate thymus at week 3.

3.7. FSP1-Expressing Fibroblast Cells in the Thymus Are Derived from Peripheral Cells. During our FACS and IHC analysis, we observed that apart from the CD45+ GFP+, CD45+ EpCAM+ GFP+, and CD45- EpCAM+ GFP+ populations, there were a significant number of GFP+ cells that did not express either CD45 or EpCAM. In addition to TECs, another nonhematopoietic contributor of the thymic stroma is fibroblasts. Recently, Fibroblast-Specific Protein-1- (FSP-1-) expressing cells were shown to help to maintain medullary thymic epithelial cells [50]. Engrafted thymi were analyzed for FSP1 expression using IHC (Figure 7). Figures 7 (a)-7(p) shows a representative figure of FSP1 staining in the transplanted thymi at different time points. The frequency of peripherally derived GFP+ cells found in the transplanted fetal lobes that express FSP1 was calculated at the different time points posttransplant. At week three, the percentage of GFP+ cells expressing FSP1 was 35% (+/-8%), while at week six, it increased to 53 (+/-13). At week nine and week twelve, the percentage increased to 71.2% (+/-8%) and 71.4% (+/-10%), respectively (Figure 7(m)). These results suggest that FSP1-expressing cells in the thymic stroma are continuously derived from cells migrating into the thymus from peripheral sources rather than through the expansion of stromal cells derived during the embryonic development of the thymus.

Journal of Immunology Research



FIGURE 5: A peripheral population can migrate into the thymus and contribute to PanK- and FoxN1-expressing thymic epithelial cells. C57BL6 fetal thymi were transplanted under the kidney capsule of actin H2BGFP mice and analyzed for the presence of GFP-expressing peripheral cells 3-12 weeks after transplant using IHC. (a–d) Week 3 transplanted thymic tissue sections showing expression of PanK (a), GFP+ peripheral cells (b), FoxN1 (c), and merged image (d). (e–h) Week 6 transplanted thymic tissue section showing expression of PanK (e), GFP+ peripheral cells (f), FoxN1 (g), and merged image (h). (i–l) Week 9 transplanted thymic tissue section showing expression of PanK (i), GFP+ peripheral cells (j), FoxN1 (k), and merged image (l). (m–p) Week 12 transplanted thymic tissue section showing expressing cells of interest are enlarged in the insets to show colocalization of both proteins and represent the cells shown in the white boxes. PanK+ FoxN1+ GFP+ cells and PanK+ FoxN1- GFP+ cells at all time points are indicated by white and red arrows, respectively. The results presented are representative of the three to five replicates of each experiment that were performed.



FIGURE 6: Reaggregate thymic organ cultures show that bone marrow-derived CD45+ EpCAM+ cells can give rise to PanK+ FoxN1+ thymic epithelial cells. (a–d) Sections of RTOC consisting of C57BL/6 fetal thymus mixed with sorted actin H2BGFP-expressing bone marrow-derived CD45+ EpCAM+ cells. A representative RTOC section showing PanK expression (a); FoxN1 expression (b) with GFP-expressing cells derived from the CD45+ EpCAM+ cells sorted from adult GFP-expressing bone marrow (c), (d) merged image of PanK, FoxN1, and GFP. GFP-, PanK-, and FoxN1-expressing cells of interest are enlarged in the insets to show coexpression of both proteins and represent the cells shown in the white boxes. (e–g) Representative 200x image of the RTOC section showing pan-keratin expression (e); staining with DAPI (f), and the merged image of PanK, and DAPI (g). A minimum of three replicates of all experiments were performed.

3.8. CD45+ EpCAM+ Cells Can Contribute to the FSP1-Expressing Fibroblasts in the Thymic Stroma In Vivo. We next wanted to investigate whether the BM-derived CD45+ EpCAM+ cells that contribute to TECs might also contribute to the peripheral populations giving rise to FSP1expressing stromal components in the thymus. RTOCs composed of sorted CD45+ EpCAM+ H2BGFP+ BM cells mixed with non-GFP-expressing fetal thymic cells were sectioned and stained with FSP1 to investigate if CD45+ EpCAM+ cells can contribute to the FSP1+ fibroblast population of the thymic stroma (Figure 8). We observed FSP1expressing H2B-GFP+ cells in the thymic stroma of RTOCs derived from both bone marrow-derived CD45+ EpCAM+ cells showing that CD45+ EpCAM+ cells can also give rise to FSP1-expressing fibroblasts.

3.9. Peripheral-Derived CD45+ EpCAM+ H2BGFP+ and CD45- EpCAM+ H2BGFP+ Result from Transdifferentiation and Not Cell Fusion. Previous studies reported that HSC cells could give rise to epithelial cells in different organs, including the liver, lung, GI tract, and skin through transdifferentiation

[36, 40]. However, these results were later disputed by Terada et al. and Wang et al., which suggested that BM-derived cells do not transdifferentiate, but they spontaneously fuse with other cells and adopt their characteristics [43, 44]. The relatively high frequency of CD45+ EpCAM+ cells observed in both the thymus and BM suggested that they were not derived from fusion. To determine if the H2BGFP-expressing TECs we observed in transplant experiments were the result of cell fusion events or true transdifferentiation, we transplanted E14.5 fetal thymuses derived from actin H2BGFP timepregnant mice under the kidney capsule of Rosa26 mRFP mice. If actin H2BGFP+ EpCAM-expressing CD45+ EpCAM+ cells and the CD45- EpCAM+ true TECs shown in Figure 4 are the result of cell fusion, then in this double transgenic model, both GFP and RFP should be expressed together on both the CD45+ EpCAM+ cells and their resulting TEC progeny. However, if the cells are genuinely derived from peripheral sources, then coexpression of both RFP and GFP in the CD45+ EpCAM+ and EpCAM+ populations should not be observed. We analyzed the transplanted thymi at two different time points 6 and 9 weeks after transplant. Analysis of



FIGURE 7: Peripheral cells migrating into the thymus contribute to FSP1-expressing fibroblasts. C57BL6 fetal thymi were transplanted under the kidney capsule of actin H2BGFP mice and analyzed 3-12 weeks after transplant using IHC. (a–c) Week 3 transplanted thymic tissue section showing the presence of GFP-expressing peripheral cells (a), FSP1-expressing cells (b), and merged image for FSP1 and GFP expression (c). (d–f) Week 6 transplanted thymic tissue section shows the presence of GFP-expressing peripheral cells (d), staining pattern for FSP1 (e), and merged image for FSP1 and GFP expression (f). (g–i) Week 9 transplanted thymic tissue section shows the presence of GFP-expressing peripheral cell (g), staining pattern for FSP1 (h), and merged image for FSP1 and GFP expression (i). (j–l) Week 12 transplanted thymic tissue section shows the presence of GFP-expressing peripheral cells (j), staining pattern for FSP1 (k), and merged image for FSP1 and GFP expression (l). GFP- and FSP1-expressing cells of interest are enlarged in the insets to show coexpression of both proteins and represent the cells shown in the white boxes. A minimum of three replicates of all experiments were performed.



FIGURE 8: Reaggregate thymic organ cultures show that both bone marrow-derived CD45+ EpCAM+ cells can give rise to FSP1+ thymic stromal cells; (a–c) RTOC consisting of C57BL/6 fetal thymus mixed with bone marrow-derived actin H2B-GFP-expressing CD45+ EpCAM+ cells. A representative RTOC section showing FSP1 expression (a); with GFP-expressing cells derived from actin H2BGFP-expressing CD45+ EpCAM+ cells sorted from adult bone marrow (b); the merged image of FSP1 and GFP (c). A minimum of three replicates were performed for each experiment.

dissociated GFP-expressing fetal lobes using flow cytometry to identify RFP and GFP 6 and 9 weeks after transplant under the kidney capsule of Rosa26 mRFP mice revealed no coexpression of GFP and mRFP in either the CD45- EpCAM+ or CD45+ EpCAM+ populations (Figure 9). mRFP+ peripheral cells were observed in all the populations, including CD45-EpCAM+ TECs. The CD45+ EpCAM+ cell population had similar frequencies of peripheral mRFP+ cells at both time points: 68% (+/-15%) and 66% (+/-15), respectively. The CD45-EpCAM+ population also contained ~1% RFP+ cells that were derived from peripheral mRFP cells migrating into the lobes. This set of results showed that peripheral CD45+ EpCAM+ cells that migrate to the thymus and contribute to the thymic stroma are not the result of cell fusion and any H2BGFP+ CD45+ EpCAM+ cells observed as well as their H2BGFP+ CD45- EpCAM+ TEC progeny represent peripheral cells migrating into the thymus and contributing to stromal components. There remains a slight possibility that the CD45+ EpCAM+ cells observed in this experiment could be derived from an earlier fusion event that occurred prior to the surgical transplant of the fetal lobes; however, we argue that the complete absence of DP cells coexpressing RFP and GFP strongly supports that they are not likely to be derived from cell fusion.

3.10. BM-Derived CD45+ EpCAM+ Cells Can Migrate to the Thymus and Contribute to the Thymus-Derived CD45+ EpCAM+ and CD45- EpCAM+ Populations under the Condition of Radiation-Induced Injury. Wong et al. showed that a CD45+ CCSP+ population in the bone marrow migrates to the lungs and contributes to the alveolar epithelial population following naphthalene-induced lung injury [40]. To understand if the CD45+ EpCAM+ population found in the bone marrow can contribute to the thymus under flowing radiation-induced injury, we partially irradi-

ated (650 cGy) four-month-old C57BL6 mice and intravenously injected ~30,000 CD45+ EpCAM+ cells sorted to high purity (>95%) from actin H2BGFP transgenic mice. Six weeks after injection, the mice were sacrificed for further analysis. The presence of H2BGFP+ cells in the dissociated thymus of injected mice would indicate that the GFPlabeled CD45+ EpCAM+ population can migrate from the bone marrow to the thymus. As a control, C57BL6 mice were irradiated with the same dose X-rays and sacrificed within 48 hours followed by thymic dissociation for FACS analysis. This was done to enable accurate gating of the GFP+ cells migrating into the thymus from the bloodstream or bone marrow. 7AAD staining was used to excluded radiation-induced dead cells from the FACS analysis. Figure 10 shows representative FACS analysis of dissociated thymic lobes. The lower part of the figure shows the analysis of C57BL/6 control mice. Since the irradiated C57BL/6 control mice were sacrificed within 48 hours, they show a higher frequency of EpCAM only TECs than our experimental mice (due to less radiation-induced death), which were analyzed 6 weeks after irradiation and CD45+ EpCAM+ cell injection. The upper part of the figure shows a representative image of irradiated C57BL/6 mice injected with H2B-GFPexpressing CD45+ EpCAM+ BM-derived cells. The injected CD45+ EpCAM+ H2BGFP-expressing cells were present in the thymus of the irradiated mice, where the frequency of GFP+ CD45+ EpCAM+ cells averaged 15% (+/-10%). Interestingly, we also observed a small but consistent presence of GFP+ CD45- EpCAM+ true TECS (2%), which could only have been derived from the injected GFP-expressing CD45 + EpCAM+ cells. These data show that the bone marrowderived CD45+ EpCAM+ population can migrate to the thymus and contribute to nonhematopoietic components of thymic stroma under the condition of radiation-induced demand for thymic recovery.



FIGURE 9: The CD45+ EpCAM+ and CD45- EpCAM+ TEC populations derived from peripheral cells are not a result of cell fusion. Actin H2B-GFP fetal thymuses were transplanted under the kidney capsule of mRFP Rosa26 mice and analyzed 6 and 9 weeks after transplant using FACS. All the experiments were done in triplicate. (a) The FACS representation of the lineage-depleted cells derived from dissociated engrafted thymi gated for CD45 and EpCAM. (b) The FACS representation of the percentage of GFP+-, GFP+ RFP+-, and RFP+-expressing cells within the CD45+ EpCAM- population at different time points. (c) The FACS representation of the percentage of GFP+-, GFP+ RFP+-, and RFP+-expressing cells within the CD45+ EpCAM+ population at different time points. (d) The FACS representation of the percentage of GFP+-, GFP+ RFP+-, and RFP+-expressing cells within the CD45+ EpCAM+ population at different time points. (e) Bar graph showing the mean percentage of the CD45+ GFP+ RFP+ (potential cell fusions) and CD45+ RFP+ (peripheral cells) populations at different time-points (error bars represent SEM). (f) Bar graph showing the mean percentages of the CD45+ EpCAM+ GFP+ RFP+ (potential cell fusions) and EpCAM+ RFP+ (peripheral cells) populations at different time points (error bars represent SEM). (g) Bar graph showing the percentages of the EpCAM+ GFP+ RFP+ (potential cell fusions) and EpCAM+ RFP+ (peripheral cells) cell populations at different time points (error bars represent SEM). (g) Bar graph showing the percentages of the EpCAM+ GFP+ RFP+ (potential cell fusions) and EpCAM+ RFP+ (peripheral cells) cell populations at different time points (error bars represent SEM). (g) Bar graph showing the percentages of the EpCAM+ GFP+ RFP+ (potential cell fusions) and EpCAM+ RFP+ (peripheral cells) cell populations at different time points (error bars represent SEM).

4. Discussion

In this study, we describe a unique, rare population in the postnatal bone marrow, which can migrate to the thymus and contribute to the thymic epithelial cell pool. This bone marrow-derived population expresses both the definitive thymic epithelial cell marker EpCAM and panhematopoietic cell marker CD45. This unique population was identified in dissociated thymic tissue as well, supporting the idea that it migrates from the bone marrow to the thymus. Immunohistochemistry and qRT-PCR results performed with highly purified sorted populations of these CD45+ EpCAM+ cells derived from both the bone marrow and the thymus showed that these cells express both CD45, EpCAM, and no expression of CD11c at both the mRNA and protein levels, confirming that they are not thymic nurse



FIGURE 10: Bone marrow-derived CD45+ EpCAM+ cells can migrate to the thymus and contribute to the thymic CD45+ EpCAM+ population, as well as CD45- EpCAM+ TECs under the condition of radiation-induced injury. CD45+ EpCAM+ GFP+ cells were sorted to greater than 99% purity from actin H2BGFP mouse bone marrow and intravenously injected into partially irradiated C57BL6 mice. The thymus was then dissociated and analyzed for the presence of GFP-expressing cells 6 weeks after transplant using FACS. (a) Representative FACS profile of the lineage-depleted cells derived from dissociated irradiated and injected thymus showing the gating strategy used analysis of live, lineage-negative cells. (a, b) The FACS representation of the lineage-depleted cells derived from dissociated irradiated and injected thymi gated for live and lineage-negative cells. (b) Representative FACS profile showing CD45 and EpCAM expression within the viable lineage-negative cells from (a) and the gating strategy used for the analysis of the CD45+ EpCAM+ and CD45-EpCAM+ subsets subsequently analyzed for GFP expression in (c) and (d). (c) Representative FACS profile showing the percentage of EpCAM+ GFP+ cells within the CD45+ EpCAM+ subset found in the thymus postirradiation and injection of DP cells and (d) representative FACS profile showing the percentage of EpCAM+ GFP+ cells within the CD45- EpCAM+ subset found in the thymus postirradiation and injection of DP cells (e-f). Identical analysis to that (a-d) above using dissociated thymus from irradiated control non-GFP-expressing C57BL/6 mice to allow proper gating on H2BGFP+ cells. (e) Gating used for viable lineage-negative dissociated thymic cells. (f) Representative FACS profile showing CD45 and EpCAM expression within the viable lineage-negative cells from (e) and the gating strategy used for the analysis of the CD45+ EpCAM+ and CD45- EpCAM+ subsets subsequently analyzed to allow proper gating for GFP expression in (g) and (h). (g) The FACS representation of the control gate for GFP-expressing cells within the CD45+ EpCAM+ subset found in the irradiated thymus and (h) the FACS representation of the control gate for GFP-expressing cells within the CD45- EpCAM+ subset found in the irradiated thymus. Four replicates of these experiments were performed.

cells, or thymic DCs as previously reported [47, 48] or an artifact derived from enzymatic dissociation of closely associated TECs and thymocytes (Figures 2 and 3).

Several previous studies suggested that bone marrowderived populations could contribute to the epithelial cell populations of different organs, including the lung, stomach, intestine, and uterus [36, 37, 40, 41]; however, these studies never identified a contribution to the thymus. In this study, for the very first time, we are showing the presence of a potential thymic epithelial progenitor cell population within the bone marrow. Analysis of C57BL6 fetal thymi, after being transplanted under the kidney capsule of actin H2BGFP mice, revealed that the CD45+ EpCAM+ population can migrate from the periphery to a growing fetal thymus and can contribute to nonhematopoietic components of the thymic stroma (Figure 4). With progressive time after transplant, the frequency of the CD45+ EpCAM+ GFP+ cell population increased and was followed by the subsequent emergence of EpCAM+ GFP+ TECs in the transplanted thymus.

IHC analysis of the same tissue showed the presence of pan-keratin and GFP-expressing cells in the transplanted tissues at all time points (Figure 5). Interestingly, pan-keratin+ FoxN1+ GFP+ cells also appear to emerge at later time points. FoxN1 is a crucial transcription factor in TEC development and thymic function, and it is a well-established marker for thymic epithelial cells. The sequential expression of FoxN1 leads us to believe that peripheral cells can migrate to the growing thymus and can contribute to thymic stroma as PanK-expressing thymic epithelial cells, which later differentiate into more mature FoxN1-expressing TEC at later time points [51, 52]. The presence of relatively abundant GFP+ cells in grafted fetal thymic lobes that did not bind the pan-keratin antibody, CD45, or FoxN1 led us to analyze the engrafted lobes for the presence of other nonhematopoietic stromal components including fibroblasts using FSP1 (a fibroblast marker). Recently, it has been shown that FSP1-expressing cells are essential for the maintenance of medullary thymic epithelial cells [50]. FSP1 staining of the transplanted tissue revealed the presence of a GFPexpressing peripherally derived FSP1+ cell population (Figure 7). We also observed with the progressive time that the number of peripherally derived GFP+ FSP1+ cells increased (Figure 7(m)).

These results together showed that a peripheral CD45+ EpCAM+ cell population could migrate to the thymus and contribute to the nonhematopoietic components of the thymic stroma. The CD45+ EpCAM+ population appears to contribute to thymic stroma in two different ways: (1) by directly giving rise to EpCAM and keratin-expressing epithelial cells and (2) by giving rise to an FSP1-expressing cell population, known to support the maintenance of the medullary thymic epithelial cell population. Limitations in the availability of antibodies to sort FSP1-expressing cells or colocalize both keratin and FSP1 on the same populations post-RTOC precluded determining whether they represented the same population or unique lineages derived from the CD45+ EpCAM+ population. Future experiments will need to be performed to determine the lineage relationship between FSP1+ GFP+ peripheral cells and PanK+ GFP+ peripherally derived TECs.

Although several previous studies showed that bone marrow-derived populations including HSCs could contribute to tissue regeneration in epithelial organs, some of this work had been refuted by subsequent studies which demonstrated that bone marrow-derived cells undergo fusion allowing them to take on characteristics of the recipient organ cell phenotype, instead of genuinely transdifferentiating [44]. Our results obtained when actin H2BGFP fetal thymus was transplanted under the kidney capsule of mRFP Rosa26 mice clearly showed that the CD45+ EpCAM+ RFP+ cell population observed in the actin H2BGFP thymus after transplant is not the result of fusion (Figure 9) since no cells coexpressing RFP and GFP were observed. The RFP+ CD45- EpCAM+ TECs observed in the transplanted thymi are derived from peripheral RFP+ cells migrating into the GFP-expressing fetal lobe.

When highly purified CD45+ EpCAM+ GFP+ cells from the bone marrow were reaggregated with non-GFP fetal thymic stroma, the GFP+ bone marrow-derived cells gave rise to pan-keratin and FoxN1-expressing true thymic epithelial cells (Figures 6(a)-6(d)), as well as FSP1-expressing fibroblast cells (Figures 8(a)-8(c)). Together, these results confirm that the CD45+ EpCAM+ cell population from bone marrow can differentiate to pan-keratin-expressing epithelial cells as well as FSP1-expressing fibroblasts.

Further, when highly purified CD45+ EpCAM+ GFP+ cells sorted from the BM of actin H2BGFP mice were intravenously injected into partially irradiated C57BL6 mice, CD45+ EpCAM+ GFP+ cells were shown to migrate to the thymus under the condition of demand induced due to injury and contribute to the CD45+ EpCAM+ population in the recovering thymic stroma. The frequency CD45+ EpCAM+ GFP+ cells in the recovering thymus is significant; however, the frequency of EpCAM+ GFP+ cells remained low. Later, time point analysis is needed to understand if a longer time is needed to observe an increase in the CD45+ EpCAM+ GFP+ population's contribution to the EpCAM-expressing TEC population or if the migration of this population decreases with the further recovery of the thymus.

In summary, this study demonstrates that a bone marrow-derived population expressing both CD45 and EpCAM can migrate and contribute to the thymic stroma and can give rise to two different nonhematopoietic cell populations in thymic stroma including both FSP1-expressing fibroblasts and keratin/FoxN1-expressing TECs under the condition of demand. It is not clear whether the CD45+ EpCAM+ cells are derived from HSCs or represent a distinct lineage of BM cells. Future studies will also need to be performed to determine the lineage relationships between the FSP1+ cells and the true keratin-expressing TECs derived from the CD45+ EpCAM+ population. They could represent distinct fates of the same population or steps in an undefined ontogeny. It is also unclear how significant the CD45+ EpCAM+ population and its progeny are to TEC homeostasis or how they might contribute to self-tolerance or T-cell selection. Previous work has suggested that the MHC background of the thymic microenvironment determines the MHC restriction of developing T-cells after BMTs [53]. If BM-derived cells are migrating into the thymus and contributing to the maintenance of TEC subsets, then it is surprising that they do not influence the MHC restriction of developing thymocytes. Further studies needed to be done to understand the ontogeny of this population and its contribution to distinct TEC subsets. If migrating CD45+ EpCAM + cells only contribute to mTECs, then it is possible that they do not influence MHC restriction but might contribute to self-tolerance through negative selection or the development of regulatory T-cell (Tregs).

Despite the presence of a progenitor cell population in BM that can contribute to TECs, the thymus still undergoes age-related involution. Understanding the lineage of the CD45+ EpCAM+ BM population as well as the mechanisms responsible for the migration of this population to the thymus and how they contribute to the maintenance of TEC number and organization will be critical in counteracting ageassociated involution, particularly in cancer patients, due to enhanced degeneration in response to therapy. This study addresses a significant unmet clinical need for thymus reconstitution by defining the contribution of bone marrow-derived thymic epithelial progenitor cells (TEPC) to the maintenance of TEC microenvironments in the postnatal thymus. It should provide an additional target for overcoming thymic atrophy and hence, the development of more strategic therapies for immunological-based diseases and cancer.

Data Availability

The flow cytometric, qRT-PCR, and immunohistochemical data used to support the findings of the study are included within the article.

Additional Points

Key Points. CD45+ EpCAM+ TEC progenitor cells are found in mouse bone marrow and thymus. Peripheral cells contribute to the thymic stroma, including TECs. Bone marrowderived CD45+ EpCAM+ cells contribute to TECs in RTOCs.

Disclosure

This manuscript is part of the Ph.D. dissertation thesis of Shami Chakrabarti, Biochemistry Department, The Graduate Center, CUNY. Above mentioned thesis can be found in the following link: https://academicworks.cuny.edu/cgi/ viewcontent.cgi?article=5283&context=gc_etds.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We would like to thank Jeffrey Walker for his outstanding flow cytometry support. This work was supported by the NIH/ NIAID 1SC1AI081527, NIH/NIAID 9SC1AI04994, NIH-NCI U54CA137788/U54CA132378, NIMHHD 8G12MD007603, and PSCCUNY TRADB-51-445.

Supplementary Materials

Supplementary Figure 1: gating strategy for FACS analysis of the lineage-depleted bone marrow- and thymus-derived CD45+ EpCAM+ cell populations. (A) Gating strategy for live cells in bone marrow analysis: SSC A vs. FSC A; (B) gating for doublet discrimination of live cells: SSC W vs. SSC H; (C) gating strategy for doublet discrimination of live cells: FSC W vs. FSC H; (D) gating for lineage-negative single cells using a cocktail of lineage antibodies including CD11b, CD11c, and CD19; (E) the FACS representation of the lineage-depleted cells derived from bone marrow gated for CD45 and EpCAM; (F) the FACS representation of the lineage-depleted cells derived from bone-marrow gated stained with CD45 together with the EpCAM using isotype

control used to set the gate for EpCAM staining; (G) the FACS representation of the lineage-depleted cells derived from the bone marrow of nude mice gated for CD45 and EpCAM; (H) gating strategy for live cells in the analysis of dissociated thymus: SSC A vs. FSC A; (I) gating for doublet discrimination of live cell: SSC W vs. SSC H; (J) gating for doublet discrimination of live cell: FSC W vs. FSC H; (K) gating for lineage-negative single cells using a cocktail of lineage antibodies including CD11b, CD11c, and CD19; (L) the FACS representation of the lineage-depleted cells derived from dissociated thymus gated for CD45 and EpCAM; (M) the FACS representation of the lineage-depleted cells derived from dissociated thymus gated for CD45 and EpCAM using the isotype control for EpCAM staining to allow proper gating of EpCAM expression. Supplementary Figure 2: FACS representation of the sort purity of bone marrow- and thymus-derived CD45+ EpCAM+ cells and the other control cell populations used for RNA isolation. (A) The FACS representation of the gating strategy used for sorting the thymus-derived CD45+ EpCAM+, CD45+ EpCAM-, and CD45- EpCAM+ subsets; (B-E) the FACS representation showing the purity of the live-gated (B) and thymusderived CD45+ EpCAM+ (C), CD45- EpCAM+ (D), and CD45+ EpCAM- (E) subsets; (F) the FACS representation of the gating strategy used for sorting the BM-derived CD45+ EpCAM+ and CD45+ EpCAM- subsets; (G-I) the FACS representation showing the purity of the live-gated (G) and BM-derived CD45+ EpCAM+ (H) and CD45+ EpCAM- (I) subsets. Supplementary Figure 3: presence of a CD45+ pan-keratin+ population in adult thymic sections. Dexamethasone-treated murine thymuses were sectioned and stained for CD45 and pan-cytokeratin. (A) Showing a maximum intensity projection of CD45 staining; (B) showing maximum intensity projection of pan-keratin staining; (C) showing maximum intensity projection of DAPI staining; (D) showing maximum intensity projection of merged CD45 and EpCAM staining. CD45- and EpCAMexpressing cells of interest are enlarged in the insets to show coexpression of both proteins and represent the cell shown in the white boxes. Supplementary Figure 4: (A-C) shows week 12 images of the transplanted fetal thymus. In this figure, the kidney is visible in the lower part of each image. This figure clearly shows a properly developed transplanted thymus at 12th week. (Supplementary Materials)

References

- G. Anderson and Y. Takahama, "Thymic epithelial cells: working class heroes for T cell development and repertoire selection," *Trends in Immunology*, vol. 33, no. 6, pp. 256– 263, 2012.
- [2] J. C. Zúñiga-Pflücker, "T-cell development made simple," *Nature Reviews Immunology*, vol. 4, no. 1, pp. 67–72, 2004.
- [3] G. Anderson, N. C. Moore, J. J. Owen, and E. J. Jenkinson, "Cellular interactions in thymocyte development," *Annual Review of Immunology*, vol. 14, no. 1, pp. 73–99, 1996.
- [4] Y. Takahama, "Journey through the thymus: stromal guides for T-cell development and selection," *Nature Reviews Immunology*, vol. 6, no. 2, pp. 127–135, 2006.

- [5] G. Anderson, E. J. Jenkinson, and H. R. Rodewald, "A roadmap for thymic epithelial cell development," *European Journal of Immunology*, vol. 39, no. 7, pp. 1694–1699, 2009.
- [6] A. Barbouti, K. Evangelou, I. S. Pateras et al., "In situ evidence of cellular senescence in thymic epithelial cells (TECs) during human thymic involution," *Mechanisms of Ageing and Development*, vol. 177, pp. 88–90, 2019.
- [7] S. Cepeda and A. V. Griffith, "Thymic stromal cells: roles in atrophy and age-associated dysfunction of the thymus," *Experimental Gerontology*, vol. 105, pp. 113–117, 2018.
- [8] B. Chakravarti and G. N. Abraham, "Aging and T-cellmediated immunity," *Mechanisms of Ageing and Development*, vol. 108, no. 3, pp. 183–206, 1999.
- [9] D. H. D. Gray, N. Seach, T. Ueno et al., "Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells," *Blood*, vol. 108, no. 12, pp. 3777–3785, 2006.
- [10] H. E. Lynch, G. L. Goldberg, A. Chidgey, M. R. M. van den Brink, R. Boyd, and G. D. Sempowski, "Thymic involution and immune reconstitution," *Trends in Immunology*, vol. 30, no. 7, pp. 366–373, 2009.
- [11] H.-R. Rodewald, "Thymus organogenesis," Annual Review of Immunology, vol. 26, no. 1, pp. 355–388, 2008.
- [12] J. Abramson and G. Anderson, "Thymic epithelial cells," *Annual Review of Immunology*, vol. 35, no. 1, pp. 85–118, 2017.
- [13] G. Anderson, S. Baik, J. E. Cowan et al., Mechanisms of thymus medulla development and Function, Springer, 2013.
- [14] E. F. Lind, S. E. Prockop, H. E. Porritt, and H. T. Petrie, "Mapping precursor movement through the postnatal thymus reveals specific microenvironments supporting defined stages of early lymphoid development," *Journal of Experimental Medicine*, vol. 194, no. 2, pp. 127–134, 2001.
- [15] C. Blanpain, V. Horsley, and E. Fuchs, "Epithelial stem cells: turning over new leaves," *Cell*, vol. 128, no. 3, pp. 445–458, 2007.
- [16] S. Baik, E. J. Jenkinson, P. J. L. Lane, G. Anderson, and W. E. Jenkinson, "Generation of both cortical and Aire+ medullary thymic epithelial compartments from CD205+ progenitors," *European Journal of Immunology*, vol. 43, no. 3, pp. 589–594, 2013.
- [17] C. C. Bleul, T. Corbeaux, A. Reuter, P. Fisch, J. S. Mönting, and T. Boehm, "Formation of a functional thymus initiated by a postnatal epithelial progenitor cell," *Nature*, vol. 441, no. 7096, pp. 992–996, 2006.
- [18] S. W. Rossi, A. P. Chidgey, S. M. Parnell et al., "Redefining epithelial progenitor potential in the developing thymus," *European Journal of Immunology*, vol. 37, no. 9, pp. 2411– 2418, 2007.
- [19] S. W. Rossi, W. E. Jenkinson, G. Anderson, and E. J. Jenkinson, "Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium," *Nature*, vol. 441, no. 7096, pp. 988–991, 2006.
- [20] Y. Hamazaki, H. Fujita, T. Kobayashi et al., "Medullary thymic epithelial cells expressing Aire represent a unique lineage derived from cells expressing claudin," *Nature Immunology*, vol. 8, no. 3, pp. 304–311, 2007.
- [21] H.-R. Rodewald, S. Paul, C. Haller, H. Bluethmann, and C. Blum, "Thymus medulla consisting of epithelial islets each derived from a single progenitor," *Nature*, vol. 414, no. 6865, pp. 763–768, 2001.

- [22] S. Shakib, G. E. Desanti, W. E. Jenkinson, S. M. Parnell, E. J. Jenkinson, and G. Anderson, "Checkpoints in the development of thymic cortical epithelial cells," *The Journal of Immunology*, vol. 182, no. 1, pp. 130–137, 2009.
- [23] A. Ucar, O. Ucar, P. Klug et al., "Adult thymus contains FoxN1⁻ epithelial stem cells that are bipotent for medullary and cortical thymic epithelial lineages," *Immunity*, vol. 41, no. 2, pp. 257–269, 2014.
- [24] S. Ulyanchenko, K. E. O'Neill, T. Medley et al., "Identification of a bipotent epithelial progenitor population in the adult thymus," *Cell Reports*, vol. 14, no. 12, pp. 2819–2832, 2016.
- [25] P. Peterson and M. Laan, "Bipotency of thymic epithelial progenitors comes in sequence," *European Journal of Immunol*ogy, vol. 43, no. 3, pp. 580–583, 2013.
- [26] C. E. Mayer, S. Žuklys, S. Zhanybekova et al., "Dynamic spatiotemporal contribution of single β5t+ cortical epithelial precursors to the thymus medulla," *European Journal of Immunol*ogy, vol. 46, no. 4, pp. 846–856, 2016.
- [27] I. Ohigashi, S. Zuklys, M. Sakata et al., "Aire-expressing thymic medullary epithelial cells originate from β5t-expressing progenitor cells," *Proceedings of the National Academy of Sciences*, vol. 110, no. 24, pp. 9885–9890, 2013.
- [28] H. M. Blau, T. R. Brazelton, and J. M. Weimann, "The evolving concept of a stem cell: entity or function?," *Cell*, vol. 105, no. 7, pp. 829–841, 2001.
- [29] J. Gordon and N. R. Manley, "Mechanisms of thymus organogenesis and morphogenesis," *Development*, vol. 138, no. 18, pp. 3865–3878, 2011.
- [30] D. H. D. Gray, A. P. Chidgey, and R. L. Boyd, "Analysis of thymic stromal cell populations using flow cytometry," *Journal of Immunological Methods*, vol. 260, no. 1-2, pp. 15–28, 2002.
- [31] M. Sekai, Y. Hamazaki, and N. Minato, "Medullary thymic epithelial stem cells maintain a functional thymus to ensure lifelong central T cell tolerance," *Immunity*, vol. 41, no. 5, pp. 753–761, 2014.
- [32] M. Osada, V. J. Singh, K. Wu, D. B. Sant'Angelo, and M. Pezzano, "Label retention identifies a multipotent mesenchymal stem cell-like population in the postnatal thymus," *PloS one*, vol. 8, no. 12, article e83024, 2013.
- [33] K. Wong, N. L. Lister, M. Barsanti et al., "Multilineage potential and self-renewal define an epithelial progenitor cell population in the adult thymus," *Cell Reports*, vol. 8, no. 4, pp. 1198–1209, 2014.
- [34] M. Dumont-Lagacé, H. Gerbe, T. Daouda et al., "Detection of quiescent radioresistant epithelial progenitors in the adult thymus," *Frontiers in Immunology*, vol. 8, p. 1717, 2017.
- [35] R. E. Bittner, C. Schöfer, K. Weipoltshammer et al., "Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice," *Anatomy and Embryol*ogy, vol. 199, no. 5, pp. 391–396, 1999.
- [36] D. S. Krause, N. D. Theise, M. I. Collector et al., "Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell," *Cell*, vol. 105, no. 3, pp. 369–377, 2001.
- [37] E. Lagasse, H. Connors, M. Al-Dhalimy et al., "Purified hematopoietic stem cells can differentiate into hepatocytes *in vivo*," *Nature Medicine*, vol. 6, no. 11, pp. 1229–1234, 2000.
- [38] É. Mezey, K. J. Chandross, G. Harta, R. A. Maki, and S. R. McKercher, "Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow," *Science*, vol. 290, no. 5497, pp. 1779–1782, 2000.

- [39] A. P. Wong, A. E. Dutly, A. Sacher et al., "Targeted cell replacement with bone marrow cells for airway epithelial regeneration," *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 293, no. 3, pp. L740–L752, 2007.
- [40] A. P. Wong, A. Keating, W.-Y. Lu et al., "Identification of a bone marrow-derived epithelial-like population capable of repopulating injured mouse airway epithelium," *The Journal* of Clinical Investigation, vol. 119, no. 2, pp. 336–348, 2009.
- [41] N. D. Theise, S. Badve, R. Saxena et al., "Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation," *Hepatology*, vol. 31, no. 1, pp. 235–240, 2000.
- [42] N. D. Theise, M. Nimmakayalu, R. Gardner et al., "Liver from bone marrow in humans," *Hepatology*, vol. 32, no. 1, pp. 11– 16, 2000.
- [43] N. Terada, T. Hamazaki, M. Oka et al., "Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion," *Nature*, vol. 416, no. 6880, pp. 542–545, 2002.
- [44] X. Wang, H. Willenbring, Y. Akkari et al., "Cell fusion is the principal source of bone-marrow-derived hepatocytes," *Nature*, vol. 422, no. 6934, pp. 897–901, 2003.
- [45] X. Borue, S. Lee, J. Grove et al., "Bone marrow-derived cells contribute to epithelial engraftment during wound healing," *The American Journal of Pathology*, vol. 165, no. 5, pp. 1767– 1772, 2004.
- [46] S. R. Amend, K. C. Valkenburg, and K. J. Pienta, "Murine hind limb long bone dissection and bone marrow isolation," *JoVE* (*Journal of Visualized Experiments*), vol. 110, no. 110, article e53936, 2016.
- [47] Y. Nakagawa, I. Ohigashi, T. Nitta et al., "Thymic nurse cells provide microenvironment for secondary T cell receptor α rearrangement in cortical thymocytes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 50, pp. 20572–20577, 2012.
- [48] C. Koble and B. Kyewski, "The thymic medulla: a unique microenvironment for intercellular self-antigen transfer," *Journal of Experimental Medicine*, vol. 206, no. 7, pp. 1505– 1513, 2009.
- [49] T. Ouchi, G. Nakato, and M. C. Udey, "EpCAM expressed by murine epidermal Langerhans cells modulates immunization to an epicutaneously applied protein antigen," *Journal of Investigative Dermatology*, vol. 136, no. 8, pp. 1627–1635, 2016.
- [50] L. Sun, C. Sun, Z. Liang et al., "FSP1⁺ fibroblast subpopulation is essential for the maintenance and regeneration of medullary thymic epithelial cells," *Scientific Reports*, vol. 5, no. 1, p. 14871, 2015.
- [51] M. Nehls, B. Kyewski, M. Messerle, and R. Waldschutz, "Two genetically separable steps in the differentiation of thymic epithelium," *Science*, vol. 272, no. 5263, pp. 886–889, 1996.
- [52] H. J. Vaidya, A. B. Leon, and C. Clare Blackburn, "FOXN1 in thymus organogenesis and development," *European Journal* of Immunology, vol. 46, no. 8, pp. 1826–1837, 2016.
- [53] F. Hashimoto, K. Sugiura, K. Inoue, and S. Ikehara, "Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo," *Blood*, vol. 89, no. 1, pp. 49–54, 1997.